AUTHORS
Yue Han, MD,PhD, Hong Tian2, Feng Xue, MD3, Changcheng Zheng, MD4, Peng CHENG, MD5, Yu Yan, MD6, Yun Chen7, Zhuan Zhen Zheng8, Lijun Xia, MD, PhD9, Lu Cheng10, Depei Wu, MD, PhD11, Jun Xu, PhD12
AFFILIATIONS
1 The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
2 The First Affiliated Hospital of Soochow University,, Suzhou, China
3 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China
4 The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui, China
5 The First Affiliated Hospital of Guangxi Medical University, Guilin, Guangxi, China
6 North China University of Science and Technology Affiliated Hospital, Tangshan, China
7 Jinan Central Hospital, Jinan, China
8 The Second Hospital of Shanxi Medical University, Taiyuan, China
9 Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States
10 Shanghai RAAS Blood Products Co., Ltd, Shanghai, China
11 The First Affiliated Hospital of Soochow University, Suzhou, China
12 Shanghai RAAS Blood Products Co., Ltd, Shanghai, China
ABSTRACT
Background: von Willebrand disease (VWD) is the most common inherited bleeding disorder. However, bleeding prophylaxis in VWD patients is currently limited to intravenous VWF replacement therapy. Activated protein C (APC) physiologically restrains thrombin amplification at vascular injury sites by inactivating factors Va and VIIIa, while exerting anti-inflammatory and cytoprotective effects. SR604 is a humanized monoclonal antibody that selectively inhibits the anticoagulant activity of APC while preserving its anti-inflammatory and cytoprotective function. In a separate phase I/II clinical study, subcutaneous injections of SR604 every 4 weeks have demonstrated favorable safety and efficacy in patients with hemophilia. The ongoing phase II study evaluates the prophylactic efficacy and safety of SR604 in patients with VWD.
Methods: This randomized, open-label, multicenter phase II trial (NCT07640893) enrolls adults with VWD who have had ≥ 4 bleeding events during the preceding 6 months. Participants are randomized 1:1:1:1 to subcutaneous SR604 at 0.2 mg/kg every 4 weeks (Q4W, Group A), 0.4 mg/kg Q4W (Group B), 0.4 mg/kg every 6 weeks (Group C), or 0.4 mg/kg every 8 weeks (Group D). The initial treatment period is 24 weeks, with an optional 24-week extension. The preliminary efficacy-evaluable population and safety population included participants who completed ≥ 12 weeks of treatment.
Results: As of July 29, 2026, 16 participants had received ≥ 1 dose of SR604. Median age was 30 years (18–53 years; 8 males and 8 females). Among them, 7 participants had completed ≥ 12 weeks of treatment (median 17.9 weeks, range 12.9–23.3), with 2 participants in each of Group A, B, and C and 1 in Group D. All 7 participants had type 3 VWD.
During the 6-month pretreatment period, the median annualized bleeding rate for all bleeding episodes (all-bleed ABR) was 46.0 (range, 8.0–104.0). During SR604 prophylaxis, the median all-bleed ABR was 13.0 (range, 2.2–38.7), 71.7% lower than the pretreatment median. Median on-treatment spontaneous and traumatic ABRs were each 6.5 (ranges, 0–30.3 and 0–10.0, respectively). The median treated ABR was 2.2 (range, 0–6.6), and the median treated spontaneous ABR was 0 (range, 0–4.4).
Six participants (85.7%) experienced 31 treatment-emergent adverse events, all grade 1 or 2. Two events, both injection-site reactions, were considered related to SR604. No adverse event resulted in dose interruption or treatment discontinuation, and no serious adverse events occurred. There were no thrombotic events. No clinically relevant changes in coagulation parameters, including fibrinogen, D-dimer, and fibrin degradation products, occurred throughout the study.
Conclusions: These preliminary findings provide the first clinical evaluation of selective APC inhibition as a non-factor prophylactic strategy in VWD. Preliminary results from this ongoing phase II study suggest that subcutaneous SR604 prophylaxis is associated with reduced bleeding in patients with type 3 VWD. No thrombotic events or treatment-related serious adverse events have been observed to date. These findings support continued evaluation of SR604 as a convenient and long-acting prophylactic therapy for VWD.
DISCLOSURES
Jun Xu, PhD: Shanghai RAAS Blood Products Co., Ltd - Current equity holder in publicly-traded company; Shanghai RAAS Blood Products Co., Ltd - Current Employment